Stealth Mode
AI Compliance Intelligence for Regulated Industries
Haliya is building the tools to detect bias and ensure compliance in pharmaceutical and healthcare documentation, before regulators do.
Haliya is building the tools to detect bias and ensure compliance in pharmaceutical and healthcare documentation, before regulators do.
AI is showing up in clinical decisions, regulatory submissions and legal documentation. The risk of undetected bias is growing fast and most organizations aren't set up to catch it.
We're building a compliance detection platform for pharmaceutical and healthcare companies operating under California jurisdiction. Our initial focus is on California's regulatory framework with plans to expand across federal and international standards including the FDA and EU AI Act.
California and federal regulators are introducing AI bias mandates. Organizations without proactive detection face enforcement actions, delayed approvals and market access barriers.
Compliance teams spend hundreds of hours manually reviewing clinical documents for bias indicators. The volume of AI-touched documentation is outpacing human review capacity.
Biased AI in clinical trials and treatment recommendations leads to inequitable patient outcomes, particularly across demographic groups that are historically underrepresented in medical research.
Healthcare organizations face growing litigation exposure from biased AI systems under California law. Without documented compliance processes legal teams lack the evidence to defend against bias-related claims.
Haliya helps pharma and healthcare organizations in California monitor documentation for bias, generate compliance-ready reports and get clear remediation guidance aligned with state and emerging federal regulatory frameworks.
Automated analysis of clinical review documents, regulatory submissions, and legal briefs for language-based and algorithmic bias across protected classes.
Generate reports aligned with California regulatory requirements and FDA AI/ML guidance. Ready for regulatory submission.
Get targeted recommendations for process improvements, training, data quality and policy updates prioritized by regulatory impact.
Connects with existing pharma and healthcare document workflows. Security and privacy standards are built in from the start.
Portfolio-level visibility into bias risk across all organizational documentation, with executive reporting and trend analysis.
Document-level bias findings and risk assessments designed for inclusion in regulatory submissions and legal proceedings.
Technical bias metrics and threshold configuration to ensure AI-powered products meet compliance requirements before deployment.
Selected for the National Science Foundation I-Corps program through the Northwest Hub. We talked to dozens of compliance leaders, regulatory affairs teams, and healthcare executives across pharma and healthcare to validate the problem and shape what we're building.
Active member of the Silicon Valley Tech Futures Group alongside other founders, investors and industry advisors in emerging tech. Key source of mentorship and strategic guidance for Haliya's go-to-market and product roadmap.
Haliya officially incorporated as a corporation in March 2026, based in the SF Bay Area, California.
Accepted into NVIDIA Inception. The program provides internal benefits for product development and VC connections as we scale our compliance detection platform.
Haliya is currently in stealth development out of the SF Bay Area. If you're at a pharma or healthcare organization navigating California's compliance detection requirements, we'd love to talk.